Triazolotriazines as kinase inhibitors

Details Triazolotriazines as kinase inhibitors Triazolotriazines as kinase inhibitors

2011-03-29

2011-03-29

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C514S243000

Reexamination Certificate

active

07915408

ABSTRACT:
The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

REFERENCES:
patent: 2837520 (1958-06-01), Fusco et al.
patent: 4209621 (1980-06-01), Dusza et al.
patent: 4405619 (1983-09-01), Heilman et al.
patent: 5236917 (1993-08-01), Dunlap et al.
patent: 5254548 (1993-10-01), Wermuth et al.
patent: 7683060 (2010-03-01), Zhuo et al.
patent: 2005/0075340 (2005-04-01), Zhang et al.
patent: 2005/0085473 (2005-04-01), Van Hirschheydt et al.
patent: 2005/0165023 (2005-07-01), Bettati
patent: 2005/0261297 (2005-11-01), Igarashi et al.
patent: 2006/0046991 (2006-03-01), Cui et al.
patent: 2006/0058303 (2006-03-01), Chambers
patent: 2007/0191376 (2007-08-01), Zou et al.
patent: 2008/0167287 (2008-07-01), Zhuo et al.
patent: 2009/0124609 (2009-05-01), Albrecht et al.
patent: 2009/0124612 (2009-05-01), Albrecht et al.
patent: 1246568 (1988-12-01), None
patent: 2158994 (1994-09-01), None
patent: 430385 (1991-06-01), None
patent: 443453 (1996-08-01), None
patent: 1640010 (2006-03-01), None
patent: 2662163 (1991-11-01), None
patent: 63037347 (1988-02-01), None
patent: 63199347 (1988-08-01), None
patent: 63310891 (1988-12-01), None
patent: 313934 (1991-01-01), None
patent: 4251243 (1992-09-01), None
patent: 5232618 (1993-09-01), None
patent: 2001043978 (2001-02-01), None
patent: WO 83/00864 (1983-03-01), None
patent: WO 99/06404 (1999-02-01), None
patent: WO 01/34603 (2001-05-01), None
patent: WO 01/34605 (2001-05-01), None
patent: WO 02/00196 (2002-01-01), None
patent: WO 02/072579 (2002-09-01), None
patent: WO 02/079203 (2002-10-01), None
patent: WO 03/080621 (2003-10-01), None
patent: WO 03/087026 (2003-10-01), None
patent: WO 03/097641 (2003-11-01), None
patent: WO 2004/005290 (2004-01-01), None
patent: WO 2004/005291 (2004-01-01), None
patent: WO 2004/020438 (2004-03-01), None
patent: WO 2004/058769 (2004-07-01), None
patent: WO 2004/076412 (2004-09-01), None
patent: WO 2005/004607 (2005-01-01), None
patent: WO 2005/004808 (2005-01-01), None
patent: WO 2005/005378 (2005-01-01), None
patent: WO 2005/010005 (2005-02-01), None
patent: WO 2005/014598 (2005-02-01), None
patent: WO 2005/028475 (2005-03-01), None
patent: WO 2005/030140 (2005-04-01), None
patent: WO 2005/039586 (2005-05-01), None
patent: WO 2005/040154 (2005-05-01), None
patent: WO 2005/040345 (2005-05-01), None
patent: WO 2005/070891 (2005-08-01), None
patent: WO 2005/073224 (2005-08-01), None
patent: WO 2005/077953 (2005-08-01), None
patent: WO 2005/097800 (2005-10-01), None
patent: WO 2005/113494 (2005-12-01), None
patent: WO 2005/121125 (2005-12-01), None
patent: WO 2006/014325 (2006-02-01), None
patent: WO 2006/018727 (2006-02-01), None
patent: WO 2006/124354 (2006-11-01), None
patent: WO 2007/008539 (2007-01-01), None
patent: WO 2007/013673 (2007-02-01), None
patent: WO 2007/015866 (2007-02-01), None
patent: WO 2007/025090 (2007-03-01), None
patent: WO 2007/064797 (2007-06-01), None
patent: WO 2007/075567 (2007-07-01), None
patent: WO 2007/096764 (2007-08-01), None
patent: WO 2008/008539 (2008-01-01), None
patent: WO 2008/051805 (2008-05-01), None
patent: WO 2008/058126 (2008-05-01), None
patent: WO 2008/144767 (2008-11-01), None
patent: WO 2009/091374 (2009-07-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Freshney et al.,Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4.
Dermer et al., Bio/Technology, 1994, 12:320.
Powell et al., British Journal of Dermatology, 141: 802-810, 1999.
Cohen et al., Current Opinion in Chemical Biology, 3,459-465, 1999.
Golub et al., Science, 286, 531-537, 1999.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & Therapeutics 93, 79-98, 2002.
Accornero et al., “An In vivo Model of Met-Driven Lymphoma as aTool to Explore the Therapeutic Potential of Met Inhibitors”,Clin Cancer Res14(7):2220-26 (2008).
Chattopadhyay et al., “Small Molecule c-Met Inhibitor PHA665752: Effect on Cell Growth and Motility in Papillary Thyroid Carcinoma”, DOI: 10.1002/hed.v30:8, pp. 991-1000, Epub Mar. 7, 2008 in WileyInterScience (www.interscience.wiley.com); http://onlinelibrary.wiley.com/doi/10.1002/hed.20816/full.
Christensen et al., “A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met Dependent Phenotypes In Vitro and Exhibits Cytoreductive Antitumor Activity In Vivo”,Cancer Res.63:7345-7355 (2003).
Garcia, et al., “Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose”,Journal of Clinical Oncology,2007 ASCO Annual Meeting Proceedings Part I. vol. 25, No. 18S (Jun. 20 Supplement), 3525 (2007) (abstract only—2 pages).
Jin et al., “MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival”, Cancer Res 68(11):4360-68 (2008).
Kong-Beltran et al., “Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer”,Cancer Res.66(1):283-289 (2006).
Morotti et al., “K252a inhibits the oncogenic properties of Met, the HGF receptor”,Oncogene,(2002) 21, pp. 4885-4893.
Mukohara et al., “Inhibition of the Met Receptor in Mesothelioma”,Clin Cancer Res11(22):8122-30 (2005).
Puri et al., “c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma”,Clin Cancer Res13(7):2246-53 (2007).
Sawada et al., “c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion”,Cancer Res67(4):1670-79 (2007).
Seiwert et al., “The MET Receptor Tyrosine Kinase is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma”,Cancer Res69(7):3021-31 (2009).
Smolen et al., “Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752”,PNAS,vol. 103( 7):2316-21 (2006).
Son et al., “Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice”,J Hepatol.,45(5):688-95 (2006), Epub May 30, 2006.
Taulli et al., “Validation of Met as a Therapeutic Target in Alveolar and Embryonal Rhabdomyosarcoma”,Cancer Res66(9):4742-49 (2006).
Ma et al., “Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non—Small Cell Lung Cancer”,Cancer Res65(4):1479-88 (2005).
Ma et al., “Downstream signaling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumor invasion”,British J. Cancer, 97:368-77 (2007).
Martens et al., “A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo”,Clin Cancer Res12(20):6144-52 (2006).
Abdel-Rahman, R. M.; Seada, M.; Fawzy, M.; El-Baz, Ibrahim, “Synthesis of some new thioethers of 1,2,4-triazine-3-hydrazones and assays for their anticancer and antihuman immune virus activities,” Farmaco (1993), 48(3), 397-406, CODEN: FRMCE8; ISSN: 0014-827X.
Alarçon et al., “Unusual Ring Closure Reaction of Amides with Pyrimidines: Novel Stereoselective Synthesis of Hexahydroimidazo[1,2-c]pyrimidines.”Synthesis, 12:2124-2130, 1999.
Balkovetz, Daniel, and Lipschutz, Joshua, “Hepatocyte Growth Factor and the Kidney: It Is Not Just For The Liver,”Intl. Rev. of Cytology, 186:225-250, 1999.
Birchmeier et al., “Met, Metastasis, Motility, and More.”Nature, 4:915-925, Dec. 2003.
Blom et al., “Preparative LC-MS Purification: Improved Compound-Specific Method Optimization.”J. Comb. Chem.,6:874-883, 2004.
Blume-Jensen, Peter, and Hunter, Tony, “Oncog

Affiliated with

Also associated with

Rating

Triazolotriazines as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triazolotriazines as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolotriazines as kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2631243